Journal of Bone and Joint Surgery - British Volume, Vol 89-B, Issue 7, 851-857.

The role of polymethylmethacrylate bone cement in modern orthopaedic surgery

J. C. J. Webb, BSc(Hons), MBChB(Hons), FRCS(Trauma & Orth), Orthopaedic Specialist Registrar1; and R. F. Spencer, MD, FRCS, FCS(SA)Orth, Consultant Orthopaedic Surgeon2

1 Avon Orthopaedic Centre, Southmead Hospital, Bristol BS10 5NB, UK.
2 Weston General Hospital, Grange Road, Weston-super-Mare, BS23 4TQ, UK.

Correspondence should be sent to Mr J. C. J. Webb; e-mail: jcjwebb{at}doctors.org.uk

 
Polymethylmethacrylate remains one of the most enduring materials in orthopaedic surgery. It has a central role in the success of total joint replacement and is also used in newer techniques such as percutaneous vertebroplasty and kyphoplasty.

This article describes the current uses and limitations of polymethylmethacrylate in orthopaedic surgery. It focuses on its mechanical and chemical properties and links these to its clinical performance. The behaviour of antibiotic-loaded bone cement are discussed, together with areas of research that are now shedding light upon the behaviour of this unique biomaterial.

 

          Introduction

 
Polymethylmethacrylate (PMMA) was first employed by orthopaedic surgeons over 60 years ago1,2 and remains a key component of modern practice. The material is not strictly a cement, but a grout. The understanding of its properties has evolved and progressed alongside the advance of the specialty, and has indirectly helped improve implant design, particle science, cell biology and biomechanics. Fixation of components in total joint replacement with cement was followed by applications in fracture and tumour surgery, and latterly, percutaneous vertebroplasty.3,4 The use of acrylic by orthopaedic surgeons is likely to continue, and knowledge of the properties and applications of this material remains essential.

Polymethylmethacrylate was unveiled by the chemical industry in 1843 and named ‘acide acrylique’ on account of the acrid smell of the monomer.5 In 1936 it was noted that mixing ground polymer with monomer produced a dough that could be manipulated and moulded; hence it became one of the early biomaterials. Early applications were in dentistry.6 In 1945 and 1950 respectively, Scales and Herschell7 and Judet and Judet8 employed PMMA prostheses of the femoral head for arthritis of the hip. Its use as a grout to improve implant fixation was pioneered in 1953 by Haboush.9 However, the major breakthrough in the use of PMMA in total hip replacement (THR) was the work of Charnley10 in 1970 who used it to secure fixation of the acetabular and femoral components and to transfer loads to bone.

          Chemistry

The structure of methylmethacrylate monomer allows polymerisation at room temperature to produce solid PMMA.11 The avidity of the polymer to dissolve in monomer aids this reaction. The contents of commercial packs of cement, including additives, are listed in Table IGo. The molecular weight of PMMA varies between proprietary brands and according to the method of sterilisation. Gamma radiation shortens the polymer chains, probably affecting many mechanical properties, but this does not occur with ethylene oxide sterilisation.12


                                 Table I. Commercial constituents of bone cement

 

Table I. Commercial constituents of bone cement

Constituent

Role

 

Powder components

    Polymer

Polymethylmethacrylate

    Co-polymers (e.g. MA-MMA*)

Alter physical properties of the cement

    Barium sulphate or zirconium dioxide

Radio-opacifiers

    Antibiotics{dagger}

Antimicrobial prophylaxis

    Dye (e.g. chlorophyll)

Distinguish cement from bone

Liquid components

    Monomer

Methylmethacrylate monomer

    N,N-dimethyl-p-toluidine (DMPT)

Initiates cold curing of polymer

    Benzoyl peroxide

Reacts with DMPT to catalyse polymerisation

    Hydroquinone

Stabiliser preventing premature polymerisation

    Dye (e.g. chlorophyll)

Distinguish cement from bone

 

 

* MA-MMA, methacrylate-methylmethacrylate

{dagger}plain bone cements do not contain antibiotics

 

 

            Working properties and viscosity

 
The dynamic viscosity ({eta}) of fluids is denoted by shear stress (F)/shear rate (S) [{eta} = F/S]. Fluids are designated as Newtonian if shear stress is linearly related to shear rate. Cement in its liquid phase of curing behaves as a non-Newtonian fluid with viscosity decreasing as shear rate is increased. This is called pseudo-plastic or shear thinning behaviour.13 However, the viscosity of all cements increases during polymerisation as the polymer chains lengthen. Manufacturers can alter the viscosity of cement by changing the molecular weight, by using co-polymers, and by varying the methods of sterilisation.14 In addition, the curing process itself can be controlled by altering the proportions of the initiator (Toluidine) and the monomer, and this can change the working properties.

The cement must be liquid enough during the working phase to be forced through a delivery device and then flow under pressure to penetrate the interstices of cancellous bone, achieving micro-interlock.10,15 Manufacturers produce cements of varying viscosities:14

Low.
These have a long waiting phase of three minutes, also known as a sticky phase. The viscosity rapidly increases during the working phase and the hardening phase is one to two minutes long.

Medium.
There is a long waiting phase of three minutes, but during the working phase, the viscosity only increases slowly. Hardening takes between one minute 30 seconds, and two minutes 30 seconds.

High.
A short waiting/sticky phase is followed by a long working phase. The viscosity remains constant until the end of the working phase. The hardening phase lasts between one minute 30 seconds and two minutes.

High viscosity cements are therefore forgiving for the surgeon and are in predominant use in the United Kingdom.16 However, the rates of curing are very sensitive to environmental factors. Low ambient temperatures during storing and mixing,17 and high humidity both prolong setting time.18

 

          Heat production during polymerisation

The polymerisation of PMMA is exothermic.14 Catalysts form free radicals which break the covalent C=C bonds of the monomer, allowing them to bind to the lengthening polymer chains. This reaction releases 52 KJ/mole of monomer, equating to heat production of 1.4 to 1.7 x 108 J/m3 of cement.14

The production of heat by the curing cement has been studied in vitro and in vivo and modelled using finite element analysis.19 In vitro studies have shown that the production of heat is increased by thicker cement mantles, higher ambient temperatures and an increased ratio of monomer to polymer.17 Recorded temperatures range between 70°C and 120°C.20 Collagen denatures with prolonged exposure to temperatures in excess of 56°C, and the risk of causing thermal damage to bone has been raised by several authors.20,21

However, in vivo studies have recorded lower peaks of temperature.14 In 1977, Reckling and Dillon22 measured the temperature at the bone cement interface in 20 THRs. The maximum temperature was 48°C but the range of the rise was from 3° to 17°C. These modest rises were attributed to the cooling effects of the local blood supply, the metallic stem, the large surface area of the interface and poor thermal conductivity of the cement. Harving, Soballe and Bunger23 recorded temperatures above 56°C but only for two to three minutes. Even if such temperatures may sometimes be reached, animal studies have indicated no adverse effects.24

Nevertheless, concerns regarding thermal and chemical injury persisted and much effort was expended on low exotherm alternatives. Boneloc (Biomet Inc., Warsaw, Indiana) was a methylmethacrylate/n-decylmethacrylate/isobotinyl-methacrylate (MMA/DMA/IBMA) co-polymer cement. Its setting temperature was 58°C in vitro.25 However, clinical results were poor with a rate of aseptic loosening of 34% at three years because of abnormal visco-elastic behaviour.26 Chemical changes made to the composition of cement can therefore have profound effects upon function, as can manipulation of the mix of the constituents, a feature that has been exploited for specific indications such as percutaneous vertebroplasty.

          Percutaneous vertebroplasty

 
This procedure is increasing in popularity. There are over 700 000 osteoporotic vertebral compression fractures each year in the USA, one third being symptomatic. They represent a difficult problem in management and are predicted to increase fourfold by 2050.27

Percutaneous vertebroplasty was originally developed as a treatment for angiomas,3 but its application to the osteoporotic spine has been shown to provide significant and prolonged relief of pain.4 It controls the symptoms of compression fractures by recreating mechanical stability.28 The technique involves the percutaneous transpedicular injection of low viscosity biomaterial into the vertebral body guided by an image intensifier. It has become common practice for clinicians to alter the mix constituents of the PMMA in order to facilitate the procedure.29 To ease injection they reduce viscosity by increasing the liquid to powder proportions of the mix. As detailed earlier, this would seem likely to increase the maximum setting temperature and setting time of cement,11 a cause for concern when considering the adjacent neurological and vascular structures. Another practice is the addition of extra opacifiers (barium sulphate, zirconium dioxide or powdered tungsten) to help with radiological visualisation.4,11,30 These departures from traditional practice may significantly reduce the compressive strength of the resulting cement, the former by reducing polymer chain concentrations and the latter by introducing multiple stress risers.11,31

Care should be taken when performing such unpredictable alterations especially as the mechanical properties of new percutaneous vertebroplasty biomaterials have now been described.29

          Potential pitfalls of polymethylmethacrylate cement

 
Apart from thermal necrosis there are other concerns:

  1. aseptic loosening is suggested to be a result of monomer-mediated bone damage,25

  2. during end-polymerisation there is volumetric shrinkage of the cement potentially compromising the bone/cement interface. Using a fluid displacement model, Charnley10 observed that the volume of cement increases to a maximum during polymerisation, before shrinking slightly, though not to its initial volume. Again this may be a largely theoretical concern,

  3. there is a conflict between the stiffness of cement and the adjacent bone.13 The Young’s modulus32 is 0.5 GPa to 1 GPa for cancellous bone, 15 GPa to 20 GPa for cortical bone, 2 GPa for cement, 1 GPa for titanium and 220 GPa for cobalt chrome. The cement may provide a shock-absorbing layer between elastic bone and a stiff implant. The conflict between degrees of stiffness is therefore much greater for uncemented implants,33

  4. in some instances, the cement mantle and its interfaces may be the weak link in the construct.34 The bone/cement interface is the key to the survival of a THR. The combination of matt-surfaced collared femoral stems and poor cementing technique are intrinsic to the failure of some implants. Polished collarless tapered stems have generally performed better,16,35,36

  5. cement particles were once considered a biological cause of aseptic loosening.37 However, Charnley38 believed that failure was mechanical in nature and that cement remained inert. Wear particles are now seen as primary initiators of the biological reactions in aseptic osteolysis.39

The performance of cemented THR is strongly supported by both registry figures16,36 and clinical research.35,40,41 This reflects the practice of surgeons in many countries who are comfortable with their cementing technique. The mechanical characteristics of PMMA are key to this success.


                      Mechanical considerations of polymethylmethacrylate in total hip replacement

 
The implants in THR transmit load to the bone through their interfaces.42 Cemented implants can transmit sustained loads over a larger area than uncemented prostheses. Charnley10 demonstrated that the interface area of a cemented stem was approximately 13 in2 (83.9 cm2). This was 65 times greater than the original uncemented calcar bearing stems.10

Cemented implants have two interfaces, the implant/cement junction and the bone/cement interface, both of which ensure preservation of mechanical stability. Success depends upon the surgical technique, the design of the implant and the properties of the cement.

Cemented acetabular components, generally made of ultra high molecular weight polyethylene (UHMWPE) (Young’s modulus of approximately 1 GPa), have a closer stiffness to cement and bone than they do to metal stems. Macro-interlock with cement is achieved using deep grooves in the UHMWPE, and most are overlapped to assist cement pressurisation. Transmitted forces are predominantly compressive with some shear. Charnley38 based the principles of ‘low friction arthroplasty’ on limiting these dangerous shear stresses.

Many different philosophies of design have been applied to cemented stems. The main differences between them occurs in the texture of shape and surface, which determine the nature and magnitude of forces at the interfaces because of the way they interact with cement. The survival of the bone/cement interface governs the outcome of cemented THR.

          Stem design

 
It is beyond the scope of this article to describe in detail experimental and clinical data relating to different stem designs. There are two predominant options, the matt textured (sometimes collared) or shape-closed design, and the polished collarless tapered or force-closed design. Upon loading, shape-closed designs transmit high shear, some tensile and low compressive stresses to both sets of interfaces.33 By contrast, force-closed designs have much lower shear stresses and as the wedge shape engages, compressive radial stresses predominate.33 These latter designs, exemplified by the Exeter stem (Stryker Orthopaedics, Mahwah, New Jersey), have serendipitously exploited the visco-elastic properties of PMMA.43 The surface finish is critical and matt versions of the stem have higher failure rates than polished versions despite identical geometry.44

          Mechanical properties of polymethylmethacrylate

 
Polymethylmethacrylate is a brittle, notch sensitive material. In the context of THR its relative properties are crucial. Its modulus of elasticity (Young’s modulus) is usually tested in tension and is approximately 2400 MPa. This is approximately ten times lower than that of the surrounding cortical bone and 100 times lower than that of the metal stem. It thus acts as an elastic interlayer between two stiff layers.33 Moreover, cement is less brittle in vivo than during laboratory testing, becoming more elastic when warmed. This occurs at the glass transition temperature (Tg) which varies with the molecular weight and structure of the monomer. Cement becomes saturated with water in vivo, which reduces the Tg and hence has a plasticising effect.

In 1976, Lautenschlager et al45 highlighted the lack of standardisation governing cement and the consequent difficulty in making comparisons between different studies. There are now international standards concerning biomaterials, including bone cements.46 These were updated in 2002, specifying mechanical and working properties for proprietary cements in clinical use. The International Organisation for Standardisation Document (ISO) 5833:200246 tests the working and static strength properties of bone cement under unphysiological laboratory conditions. Cement companies are required to provide a graph of the working properties with each of their packs. However, over 90% of complaints from clinical users indicate that handling in vivo does not match these properties.14

The principal problem with ISO and other testing standards is concentration on short-term static strength properties, which are poor at distinguishing between different formulations of cement and additive.14 The static properties of the leading cement brands are summarised in Table IIGo.14,25,26,47–49

Polymethylmethacrylate has the unique property of continued polymerisation in vivo but this is a prolonged process lasting for between 28 and 70 days.49 The long-term properties of bone cement, including fatigue behaviour, the visco-elastic properties of creep and stress relaxation are central to the success of cemented hip replacement33 and designs that exploit these properties have been clinically validated.36

 

          Visco-elastic properties of polymethylmethacrylate

 
The visco-elastic properties of bone cement are creep and its ‘inverse’ stress relaxation, which are both time and temperature dependent.

Creep.
This is the deformation of a material under constant load. Under constant load a material capable of creep will deform by an amount dependent on the size of the load and the length of time it is applied. The rate of loading is also important, where visco-elastic materials demonstrate a higher Young’s modulus at higher loading rates.33

Stress relaxation.
This is the time-dependent change in stress within a material under constant strain. The force needed to maintain a set deformation will reduce with time if stress relaxation occurs.

Polymers demonstrate features of both elastic solids and viscous liquids under conditions of low strain and hence are described as visco-elastic. At a molecular level, relatively weak non-covalent bonds exist between adjacent polymer side-chains, and these may be breached, resulting in visco-elastic properties. Mathematical models have been applied to this behaviour.49,50

At the implant level the trend towards polished tapered stem designs has been facilitated by the visco-elastic properties of PMMA. Robust evidence from both finite element analysis and laboratory studies indicates that the subsidence of a stem within the cement mantle by the process of creep protects the vital bone/cement interface and hence the replacement overall.51,52 This is supported by excellent clinical results using such a combination of components.36,41,44 Those who favour shape-closed designs have not exploited visco-elastic behaviour and have indeed taken measures to reduce it by altering the cement.53,54

The visco-elastic behaviour of PMMA is therefore increasingly under investigation. The creep behaviour of leading cement brands can differ significantly even though their static properties are similar.55 In vivo, cement is bathed in water which permeates the PMMA and acts as a plasticiser (internal lubricant). Plasticisers, which include unreacted monomer and lipids, increase the creep of the cement.56,57 The use of co-polymers with high hydrophilicity, such as methacrylate-methylmethacrylate (MAMMA) copolymer in Palacos cement (Heraeus Medical Gmbh, Hanau, Germany), also increases creep.2,58 Polymethylmethacrylate continues to polymerise for weeks after implantation and the creep is higher in this younger cement.49,58 The constraint of the proximal femur has a profound limiting influence on the visco-elastic properties.59

An increased understanding of the effects of additives to cement upon creep is now developing. Antibiotics increase the creep of PMMA and this appears to be related to the porosity of the cement.60 There is much yet to be discovered in this field.

          Antibiotic-loaded acrylic cement

In 1970 Buchholz and Engelbrecht61 incorporated gentamicin in PMMA for the treatment of infection in prosthetic joints. Initially the antibiotic was added by hand, and subsequently during manufacture, making antibiotic-loaded acrylic cement widely available as part of antimicrobial prophylaxis in primary arthroplasty. There is valid evidence to support the prophylactic use of antibiotic-loaded acrylic cement62 which remains standard practice in the United Kingdom, Western Europe and Scandinavia, and is in transition in the USA. In 2003 the Food and Drug Administration63 accepted the use of three commercial antibiotic-loaded acrylic cements in the second stage of revision surgery for prosthetic joint infection. Their use in primary total joint replacement remains unauthorised. The American Academy of Orthopaedic Surgeons has produced guidelines regarding the use of antibiotic-loaded acrylic cement and advises its use as a prophylactic measure only in cases where the patient has significant risk factors for infection.63

The use of antibiotic-loaded acrylic cement in joint replacement provides short- to medium-term protection against prosthetic infection. It aims to overlap with, and then replace, the prophylaxis provided by peri-operative intravenous antibiotics. To achieve this it must be released from cement in high enough concentrations to exceed the minimum inhibitory concentration of potential colonising bacteria.

The elution behaviour of acrylic bone cement has been studied extensively.64 Gentamicin is the most common additive because it has, amongst other features, a good spectrum of concentration-dependent bactericidal activity, thermal stability and high water solubility.65,66 In 1980, Wahlig and Dingeldein65 gave robust evidence of gentamicin release from Palacos cement for up to five and a half years in patients who had undergone THR. Following this they collaborated with Buchholz67 in a trial assessing the release of differing concentrations of gentamicin from Palacos cement in patients with a THR. Palacos/gentamicin was established as an ideal antibiotic delivery system.67 Others have confirmed reliable release of gentamicin from Palacos R (Heraeus Medical GMbH) cement (0.5 g per 40 g mix).68

However, concerns about antibiotics in cement still persist: Induction of antibiotic resistance. In 1989 Hope et al69 found that 90% of Staphylococcal strains isolated from infected hip replacements were resistant to gentamicin but if plain cement had been used at the initial operation the rate was only 16%. Other studies have confirmed that antibiotic-loaded acrylic cement reduces infection in total joint replacement at the price of increasing resistance.70,71

Hypersensitivity and toxic side effects.
These problems have not been demonstrated clinically, even though they have been postulated.

Unsuitable antibiotics.
Many antibiotics have been shown either to be heat labile or to cause deleterious effects upon cement. The former include flucloxacillin, and possibly other penicillins, chloramphenicol and tetracycline.64,72 An example of the latter is rifampicin, preventing setting for several days.73

Prolonged release of antibiotic.
Despite the aim of achieving early and total release, all in vitro studies show that only 5% to 8% of the added antibiotic is ever freed.74,75 Clinical studies have shown a low concentration of release of gentamicin in failing THRs up to 25 years after the primary operation,76,77 a potent stimulus for antibiotic resistance.

Adverse effects on the mechanical strength of polymethylmethacrylate.
There is a large body of work available on this issue. Antibiotics should neither be added in liquid form nor to the monomer, as this can lead to a 40% reduction in compressive strength in vitro.45 The addition of 2 g of gentamicin, cloxacillin or cefazolin to a 40 g mix of polymer has no significant effect on the short-term mechanical properties of Simplex-P (Stryker Orthopaedics) and Palacos-R (Heraeus Medical Gmbh) cements.45 Studies confirm that a 5% addition of antibiotic gives the optimal balance between elution and mechanical properties.78

There remain a number of deficiencies in the literature regarding the behaviour of antibiotic-loaded acrylic cement. Most mechanical studies have assessed the static short-term mechanical properties. These are less clinically relevant than the fatigue life or visco-elastic properties.57 Single antibiotic additives have usually been the focus of mechanical studies but this trend is now changing as the need for antibiotic combinations becomes recognised as a result of the prevalence of multi-resistant bacteria.79 There is a need for continued research into the effects of single and multiple antibiotic additives upon the static and visco-elastic properties of PMMA. These should be performed, where possible, under standardised conditions and should reflect modern techniques of cement preparations.

Polymethylmethacrylate bone cement continues to have numerous uses in orthopaedic practice. Clinicians have acquired understanding of many of its properties through both chance and direct research. Continued research is still needed into its long-term mechanical behaviour58 and its interaction with additives such as antibiotics or radio-opacifiers.

          References

  1. Kühn K-D. Properties of bone cement: what is bone cement. In: Breusch S, Malchau H, eds. The well-cemented total hip arthroplasty. Heidelberg: Springer Medizin Verlag, 2005:52–9.

  1. van de Belt H, Neut D, Schenk W, et al. Infection of orthopaedic implants and the use of antibiotic-loaded bone cements: a review. Acta Orthop Scand 2002;72:557–71.[CrossRef][ISI]

  1. Galibert P, Deramond H, Rosat P, Le Gars D. Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty. Neurochirurgie 1981;33:166–8 (in French).

  1. McGraw JK, Lippert JA, Minkus KD, et al. Prospective evaluation of pain relief in 100 patients undergoing percutaneous vertebroplasty: results and follow-up. J Vasc Interv Radiol 2002;13:883–6.[Abstract/Free Full Text]

  1. Hendriks JG, van Horn JR, van der Mei HC, Busscher HJ. Backgrounds of antibiotic-loaded bone cement and prosthesis-related infection. Biomaterials 2004;25:545–56.[CrossRef][ISI][Medline]

  1. Munson FT, Heron DF. Facial reconstruction with acrylic resin. Am J Surg 1941;3:291–50.

  1. Scales JF, Herschell W. Perspex (methylemthacrylate) in orthopaedics. Br Med J 1945:245–9.

  1. Judet J, Judet R. The use of an artificial femoral head for arthroplasty of the hip joint. J Bone Joint Surg [Br] 1950;32-B:166–73.[Abstract/Free Full Text]

  1. Haboush EJ. A new operation for arthroplasty of the hip based on biomechanics, photoelasticity, fast-setting dental acrylic, and other considerations. Bull Hosp Joint Dis 1953;14:242–77.[Medline]

  1. Charnley J. Acrylic cement in orthopaedic surgery. Baltimore: Williams and Wilkins, 1970.

  1. Nussbaum DA, Gailloud P, Murphy K. The chemistry of acrylic bone cements and implications for clinical use in image-guided therapy. J Vasc Interv Radiol 2004;15:121–6.[Abstract/Free Full Text]

  1. Lewis G, Mladsi S. Effect of sterilization method on properties of Palacos R acrylic bone cement. Biomaterials 1998;19:117–24.[CrossRef][ISI][Medline]

  1. Lewis G. Properties of acrylic bone cement: state of the art review. J Biomed Mater Res 1997;38:155–82.[CrossRef][ISI][Medline]

  1. Kühn K-D. Bone cement: up-to-date comparison of physical and chemical properties of commercial interests. Berlin: Springer, 2000.

  1. Slooff TJH. The influence of acrylic cement. Acta Orthop Scand 1971;42:465–81.[ISI][Medline]

  1. Furnes O, Espehaug B, Lie SA, et al. Prospective studies of hip and knee prostheses. The Norwegian Arthroplasty Register 1987–2004. American Academy of Orthopaedic Surgeons, 2005;23–2.

  1. Meyer PR Jr, Lautenschlager EP, Moore BK. On the setting properties of acrylic bone cement. J Bone Joint Surg [Am] 1973;55-A:149–56.

  1. Lee AJ, Ling RS, Vangala SS. Some clinically relevant variables affecting the mechanical behaviour of bone cement. Arch Orthop Trauma Surg 1978;92:1–18.[CrossRef][ISI][Medline]

  1. Hansen E. Modelling heat transfer in a bone-cement-prosthesis system. J Biomech 2003;36:787–95.[CrossRef][ISI][Medline]

  1. DiPisa JA, Sih GS, Berman AT. The temperature problem at the bone-acrylic cement interface of the total hip replacement. Clin Orthop 1976;121:95–8.[Medline]

  1. Mjoberg B, Pettersson H, Rosenqvist R, Rydholm A. Bone cement, thermal injury and the radiolucent zone. Acta Orthop Scand 1984;55:597–600.[ISI][Medline]

  1. Reckling FW, Dillon WL. The bone-cement interface temperature during total joint replacement. J Bone Joint Surg [Am] 1977;59-A:80–2.

  1. Harving S, Soballe K, Bunger C. A method for bone-cement interface thermometry: an in vitro comparison between low temperature curing cement Palavit, and Surgical Simplex P. Acta Orthop Scand 1991;62:546–8.[ISI][Medline]

  1. Linder L. Reaction of bone to the acute chemical trauma of bone cement. J Bone Joint Surg [Am] 1977;59:82–7.[Abstract/Free Full Text]

  1. Kindt-Larsen T, Smith DB, Jensen JS. Innovations in acrylic bone cement and applications equipment. J Appl Biomater 1995;6:75–83.[CrossRef][ISI][Medline]

  1. Abdel-Kader KF, Allcock S, Walker DI, Chaudhry SB. Boneloc bone-cement: experience in hip arthroplasty during a 3-year period. J Arthroplasty 2001;16:811–19.[CrossRef][ISI][Medline]

  1. Riggs BL, Melton LJ III. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17:505–11.

  1. Truumees E, Hilibrand A, Vaccaro AR. Percutaneous vertebral augmentation. Spine J 2004;4:218–29.[CrossRef][Medline]

  1. Gheduzzi S, Webb JJ, Miles AW. Mechanical characterisation of three percutaneous vertebroplasty biomaterials. J Mater Sci Mater Med 2006;17:421–26.[CrossRef][ISI][Medline]

  1. Mathis JM, Wong W. Percutaneous vertebroplasty: technical considerations. J Vasc Interv Radiol 2003;14:953–60.[Abstract/Free Full Text]

  1. Belkoff SM, Sanders JC, Jasper LE. The effect of the monomer-to-powder ratio on the material properties of acrylic bone cement. J Biomed Mater Res 2002;63:396–9.[CrossRef][ISI][Medline]

  1. Miller MD. Review of orthopaedics. Fourth ed. Philadelphia:Saunders, 2004:127.

  1. Lee AJC. The time-dependent properties of polymethylmethacrylate bone cement: the interaction of shape of femoral stems, surface finish and bone cement. In: Lear-month ID, ed. Interfaces in total hip arthroplasty. London: Springer-Verlag Ltd, 2000:11–19.

  1. Harrigan TP, Kareh JA, O’Connor DO, Burke DW, Harris WH. A finite element study of the initiation of failure of fixation in cemented femoral total hip components. J Orthop Res 1992;10:134–44.[CrossRef][ISI][Medline]

  1. Hook S, Moulder E, Yates PJ, et al. The Exeter universal stem: a minimum ten-year review from an independent centre. J Bone Joint Surg [Br] 2006;88-B:1584–90.[Abstract/Free